February 5, 2020Open Access

Comparison of Biologics and Oral Treatments for Plaque Psoriasis

Key Points

Key points are not available for this paper at this time.

Abstract

This study provides an assessment of the comparative efficacy among treatments for moderate to severe plaque psoriasis. The meta-analysis suggests that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were associated with the highest PASI response rates in both short-term and long-term therapy.

AIに質問

Bookmark

View Full Paper

Cite This Study

Armstrong et al. (Wed,) studied this question.

synapsesocial.com/papers/69d8f82c537c710c9cae2b90 https://doi.org/https://doi.org/10.1001/jamadermatol.2019.4029

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis2018 · 32 citations
2Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis2012 · 929 citations
3Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)2015 · 670 citations
4Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis2018 · 29 citations
5Old and New Biological Therapies for Psoriasis2017 · 237 citations

AIに質問

Bookmark

View Full Paper